Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Remote Controlled Drug Delivery
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Remote Controlled Drug Delivery

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: closed (20 June 2020) | Viewed by 18530

Special Issue Editors

Prof. Dr. Patricia Severino

E-Mail Website
Guest Editor
1. Department of Pharmacy, University of Tiradentes, Sergipe, Brazil
2. Tiradentes Institute, Dorchester, Boston, MA, USA
Interests: drug delivery systems; nanoparticles; modified-release formulations; lipids; polymers
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Eliana B. Souto

E-Mail Website
Guest Editor
Professor of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, 4099-002 Porto, Portugal
Interests: drug delivery; drug targeting; active pharmaceutical ingredients; volatile compounds; encapsulation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The latest breakthroughs in new biomaterials and production technologies (top–down, bottom–up), together with the understanding of the biodistribution and pharmacokinetics of drugs, are contributing to the development of a new generation of remote-controlled drug delivery systems (rc-DDS) and their use in the management of chronic diseases. Compared to traditional drug formulations, rc-DDS offer the opportunity to modify the release profile of drugs with a precise control over the drug concentration, reaching non-accessible anatomic districts in a non-invasive fashion. Rc-DDS may be tailored to precisely tune the drug release rate for a predetermined time-interval or can be directly controlled by a remote triggering mechanism of an injectable or implantable device. Colleagues are invited to participate in this Special Issue, by proposing original research articles and review papers that deal with responsive drug delivery with spatial/temporal release, aiming at improving the treatment/management of chronic diseases.

Prof. Dr. Patricia Severino
Prof. Dr. Eliana B. Souto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2452 KiB  
Article
Efficacy and Safety of Human Serum Albumin–Cisplatin Complex in U87MG Xenograft Mouse Models
by Cho Rong Park, Hyo Young Kim, Myung Geun Song, Yun-Sang Lee, Hyewon Youn, June-Key Chung, Gi Jeong Cheon and Keon Wook Kang
Int. J. Mol. Sci. 2020, 21(21), 7932; https://doi.org/10.3390/ijms21217932 - 26 Oct 2020
Cited by 19 | Viewed by 3377
Abstract
Cisplatin (cis-diamminedichloroplatinum (II), CDDP) is a chemotherapeutic drug widely used against many solid tumors. A pharmacokinetics study found that CDDP can bind to human serum albumin (HSA), which is the most abundant plasma protein in serum. HSA has the advantage of being a [...] Read more.
Cisplatin (cis-diamminedichloroplatinum (II), CDDP) is a chemotherapeutic drug widely used against many solid tumors. A pharmacokinetics study found that CDDP can bind to human serum albumin (HSA), which is the most abundant plasma protein in serum. HSA has the advantage of being a nanocarrier and can accumulate in tumors by passive targeting and active targeting mediated by the secreted protein acidic and rich in cysteine (SPARC). In this study, we investigated the possibility of using a CDDP–HSA complex (HSA–CDDP) as a SPARC-mediated therapeutic agent. To investigate the HSA-dependent therapeutic effect of HSA–CDDP, we used two types of U87MG glioma cells that express SPARC differently. HSA–CDDP was highly taken up in SPARC expressing cells and this uptake was enhanced with exogenous SPARC treatment in cells with low expression of SPARC. The cytotoxicity of HSA–CDDP was also higher in SPARC-expressing cells. In the tumor model, HSA–CDDP showed a similar tumor growth and survival rate to CDDP only in SPARC-expressing tumor models. The biosafety test indicated that HSA–CDDP was less nephrotoxic than CDDP, based on blood markers and histopathology examination. Our findings show that HSA–CDDP has the potential to be a novel therapeutic agent for SPARC-expressing tumors, enhancing the tumor targeting effect by HSA and reducing the nephrotoxicity of CDDP. Full article
(This article belongs to the Special Issue Remote Controlled Drug Delivery)
►▼ Show Figures

Figure 1

14 pages, 2587 KiB  
Article
Naringenin-Functionalized Multi-Walled Carbon Nanotubes: A Potential Approach for Site-Specific Remote-Controlled Anticancer Delivery for the Treatment of Lung Cancer Cells
by Renata P. Morais, Gabrielle B. Novais, Leandro S. Sangenito, André L. S. Santos, Ronny Priefer, Margreet Morsink, Marcelo C. Mendonça, Eliana B. Souto, Patrícia Severino and Juliana C. Cardoso
Int. J. Mol. Sci. 2020, 21(12), 4557; https://doi.org/10.3390/ijms21124557 - 26 Jun 2020
Cited by 42 | Viewed by 3886
Abstract
Multi-walled carbon nanotubes functionalized with naringenin have been developed as new drug carriers to improve the performance of lung cancer treatment. The nanocarrier was characterized by Transmission Electron Microscopy (TEM), Fourier-Transform Infrared Spectroscopy (FTIR), X-ray photoelectron spectroscopy, Raman Spectroscopy, and Differential Scanning Calorimetry [...] Read more.
Multi-walled carbon nanotubes functionalized with naringenin have been developed as new drug carriers to improve the performance of lung cancer treatment. The nanocarrier was characterized by Transmission Electron Microscopy (TEM), Fourier-Transform Infrared Spectroscopy (FTIR), X-ray photoelectron spectroscopy, Raman Spectroscopy, and Differential Scanning Calorimetry (DSC). Drug release rates were determined in vitro by the dialysis method. The cytotoxic profile was evaluated using the MTT assay, against a human skin cell line (hFB) as a model for normal cells, and against an adenocarcinomic human alveolar basal epithelial (A569) cell line as a lung cancer in vitro model. The results demonstrated that the functionalization of carbon nanotubes with naringenin occurred by non-covalent interactions. The release profiles demonstrated a pH-responsive behavior, showing a prolonged release in the tumor pH environment. The naringenin-functionalized carbon nanotubes showed lower cytotoxicity on non-malignant cells (hFB) than free naringenin, with an improved anticancer effect on malignant lung cells (A549) as an in vitro model of lung cancer. Full article
(This article belongs to the Special Issue Remote Controlled Drug Delivery)
►▼ Show Figures

Figure 1

Review

Jump to: Research

32 pages, 17287 KiB  
Review
Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials
by Denis V. Voronin, Anatolii A. Abalymov, Yulia I. Svenskaya and Maria V. Lomova
Int. J. Mol. Sci. 2021, 22(17), 9149; https://doi.org/10.3390/ijms22179149 - 24 Aug 2021
Cited by 9 | Viewed by 4722
Abstract
The increased research activity aiming at improved delivery of pharmaceutical molecules indicates the expansion of the field. An efficient therapeutic delivery approach is based on the optimal choice of drug-carrying vehicle, successful targeting, and payload release enabling the site-specific accumulation of the therapeutic [...] Read more.
The increased research activity aiming at improved delivery of pharmaceutical molecules indicates the expansion of the field. An efficient therapeutic delivery approach is based on the optimal choice of drug-carrying vehicle, successful targeting, and payload release enabling the site-specific accumulation of the therapeutic molecules. However, designing the formulation endowed with the targeting properties in vitro does not guarantee its selective delivery in vivo. The various biological barriers that the carrier encounters upon intravascular administration should be adequately addressed in its overall design to reduce the off-target effects and unwanted toxicity in vivo and thereby enhance the therapeutic efficacy of the payload. Here, we discuss the main parameters of remote-controlled drug delivery systems: (i) key principles of the carrier selection; (ii) the most significant physiological barriers and limitations associated with the drug delivery; (iii) major concepts for its targeting and cargo release stimulation by external stimuli in vivo. The clinical translation for drug delivery systems is also described along with the main challenges, key parameters, and examples of successfully translated drug delivery platforms. The essential steps on the way from drug delivery system design to clinical trials are summarized, arranged, and discussed. Full article
(This article belongs to the Special Issue Remote Controlled Drug Delivery)
►▼ Show Figures

Figure 1

16 pages, 1445 KiB  
Review
Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery
by Cecilia T. de Barros, Alessandra C. Rios, Thaís F. R. Alves, Fernando Batain, Kessi M. M. Crescencio, Laura J. Lopes, Aleksandra Zielińska, Patricia Severino, Priscila G. Mazzola, Eliana B. Souto and Marco V. Chaud
Int. J. Mol. Sci. 2020, 21(17), 5974; https://doi.org/10.3390/ijms21175974 - 19 Aug 2020
Cited by 8 | Viewed by 5455
Abstract
Cachexia, a severe multifactorial condition that is underestimated and unrecognized in patients, is characterized by continuous muscle mass loss that leads to progressive functional impairment, while nutritional support cannot completely reverse this clinical condition. There is a strong need for more effective and [...] Read more.
Cachexia, a severe multifactorial condition that is underestimated and unrecognized in patients, is characterized by continuous muscle mass loss that leads to progressive functional impairment, while nutritional support cannot completely reverse this clinical condition. There is a strong need for more effective and targeted therapies for cachexia patients. There is a need for drugs that act on cachexia as a distinct and treatable condition to prevent or reverse excess catabolism and inflammation. Due to ghrelin properties, it has been studied in the cachexia and other treatments in a growing number of works. However, in the body, exogenous ghrelin is subject to very rapid degradation. In this context, the intranasal release of ghrelin-loaded liposomes to cross the blood-brain barrier and the release of the drug into the central nervous system may be a promising alternative to improve its bioavailability. The administration of nose-to-brain liposomes for the management of cachexia was addressed only in a limited number of published works. This review focuses on the discussion of the pathophysiology of cachexia, synthesis and physiological effects of ghrelin and the potential treatment of the diseased using ghrelin-loaded liposomes through the nose-to-brain route. Full article
(This article belongs to the Special Issue Remote Controlled Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop